TY - JOUR
T1 - Serum protein S-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon - Comparison with tyrosinase RT-PCR
AU - Domingo-Domènech, J.
AU - Molina, R.
AU - Castel, T.
AU - Montagut, C.
AU - Puig, S.
AU - Conill, C.
AU - Martí, R.
AU - Vera, M.
AU - Auge, J. M.
AU - Malvehy, J.
AU - Grau, J. J.
AU - Gascon, P.
AU - Mellado, B.
PY - 2005/8
Y1 - 2005/8
N2 - Objective: To study the clinical value of the determination of serum S-100 protein as a single tumor marker or in combination with tyrosinase RT-PCR in patients with melanoma receiving adjuvant interferon. Patients and Methods: Patients were tested for serum S-100 protein luminoimmunometric assay and for blood tyrosinase mRNA (RT-PCR), before starting interferon and every 2-3 months thereafter. Results: One hundred and six patients (stage IIA, 27; IIB, 19; III, 49; and IV, 11) were included in the study. Median follow-up was 51 months (range 2-76). In the univariate analysis, under treatment S-100 ≥0.15 μg/l and a positive RT-PCR correlated with a lower disease-free survival and overall survival (OS). In the multivariate analysis, clinical stage, undertherapy positive RT-PCR and S-100 levels ≥0.15 μg/ml, were independent prognostic factors for OS. The hazard ratio for OS was 3.9 (95% CI, 1.67-9.15; p = 0.004) and 2.2 (95% CI, 1.05-4.6; p = 0.016) for S-100 ≥0.15 μg/l and positive RT-PCR, respectively. When both techniques where combined, a positive RT-PCR indicated a poorer clinical outcome only in patients with S-100 <0.15 μg/l. Conclusions: S-100 ≥0.15 μg/l and a positive RT-PCR during adjuvant interferon therapy indicate a high risk of death in resected melanoma patients. S-100 determination has a higher positive predictive value than RT-PCR, while tyrosinase RT-PCR adds prognostic information in patients with S-100 <0.15 μg/l.
AB - Objective: To study the clinical value of the determination of serum S-100 protein as a single tumor marker or in combination with tyrosinase RT-PCR in patients with melanoma receiving adjuvant interferon. Patients and Methods: Patients were tested for serum S-100 protein luminoimmunometric assay and for blood tyrosinase mRNA (RT-PCR), before starting interferon and every 2-3 months thereafter. Results: One hundred and six patients (stage IIA, 27; IIB, 19; III, 49; and IV, 11) were included in the study. Median follow-up was 51 months (range 2-76). In the univariate analysis, under treatment S-100 ≥0.15 μg/l and a positive RT-PCR correlated with a lower disease-free survival and overall survival (OS). In the multivariate analysis, clinical stage, undertherapy positive RT-PCR and S-100 levels ≥0.15 μg/ml, were independent prognostic factors for OS. The hazard ratio for OS was 3.9 (95% CI, 1.67-9.15; p = 0.004) and 2.2 (95% CI, 1.05-4.6; p = 0.016) for S-100 ≥0.15 μg/l and positive RT-PCR, respectively. When both techniques where combined, a positive RT-PCR indicated a poorer clinical outcome only in patients with S-100 <0.15 μg/l. Conclusions: S-100 ≥0.15 μg/l and a positive RT-PCR during adjuvant interferon therapy indicate a high risk of death in resected melanoma patients. S-100 determination has a higher positive predictive value than RT-PCR, while tyrosinase RT-PCR adds prognostic information in patients with S-100 <0.15 μg/l.
KW - Melanoma
KW - S-100
KW - Tyrosinase reverse transcription-polymerase chain reaction
UR - http://www.scopus.com/inward/record.url?scp=23844470897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23844470897&partnerID=8YFLogxK
U2 - 10.1159/000086973
DO - 10.1159/000086973
M3 - Article
C2 - 16020961
AN - SCOPUS:23844470897
SN - 0030-2414
VL - 68
SP - 341
EP - 349
JO - Oncology
JF - Oncology
IS - 4-6
ER -